These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37442659)

  • 61. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
    Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 64. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
    Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M
    Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
    Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
    Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.
    Snitker S; Egebjerg C; Frederiksen M; Sparre T
    Diabetes Obes Metab; 2022 Nov; 24(11):2273-2276. PubMed ID: 35791625
    [No Abstract]   [Full Text] [Related]  

  • 67. Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.
    Yin DG; Ding LL; Zhou HR; Qiu M; Duan XY
    Endocr J; 2021 Jun; 68(6):739-742. PubMed ID: 34024887
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes.
    Hedrington MS; Tsiskarishvili A; Davis SN
    Expert Opin Biol Ther; 2018 Mar; 18(3):343-351. PubMed ID: 29431519
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
    Overgaard RV; Lindberg SØ; Thielke D
    Diabetes Obes Metab; 2019 Jan; 21(1):43-51. PubMed ID: 30047216
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
    Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
    BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New Drug for Type 2 Diabetes.
    Aschenbrenner DS
    Am J Nurs; 2020 Jan; 120(1):25. PubMed ID: 31880702
    [No Abstract]   [Full Text] [Related]  

  • 72. Research digest: pioneering an oral GLP-1 receptor agonist.
    Atkinson MA; Powers AC
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):897. PubMed ID: 31748168
    [No Abstract]   [Full Text] [Related]  

  • 73. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.
    Gomez-Peralta F; Abreu C
    Drug Des Devel Ther; 2019; 13():731-738. PubMed ID: 30863012
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.
    Sani E; Prato GD; Zenti MG; Bordugo A; Trombetta M; Bonora E
    Endocr Metab Immune Disord Drug Targets; 2022; 22(10):1053-1057. PubMed ID: 35538810
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.
    Boye KS; Matza LS; Stewart KD; Jordan J; Biricolti G; Del Santo S; Perez-Nieves M; Federici MO; Gentilella R; Losi S; Norrbacka K
    J Med Econ; 2019 Aug; 22(8):806-813. PubMed ID: 31010349
    [No Abstract]   [Full Text] [Related]  

  • 77. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 78. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
    Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus
    Miyasaka K
    Nihon Yakurigaku Zasshi; 2022; 157(2):146-154. PubMed ID: 35228448
    [TBL] [Abstract][Full Text] [Related]  

  • 80. More on Semaglutide in Early Type 1 Diabetes.
    Gaglia JL; Laffel LM; Patti ME
    N Engl J Med; 2024 Jan; 390(3):291. PubMed ID: 38231642
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.